Table 2. Baseline Characteristics.

	Sertraline N=234	Placebo N=235
Demographic Characteristics
Age, mean (SD), y	62.9 (10.5)	61.4 (11.1)
Women, No. (%)	101 (43.2)	89 (37.9)
Race, No. (%)
White	131 (56)	136 (57.9)
African American	92 (39.3)	82 (34.9)
Hispanic	0 (0)	2 (0.9)
Heart Failure Characteristics
NYHA Class, No. (%)
I	0 (0)	0 (0)
II	71 (30.3)	61 (26)
III	109 (46.6)	114 (48.5)
IV	54 (23.1)	60 (25.5)
LVEF, mean (SD)	31.3 (9.5)	29.5 (10.1)
Ischemic etiology, No. (%)	163 (69.7)	163 (69.4)
≥1 heart failure hospitalization in previous 12 months, No. (%)*	134 (57.3)	158 (67.2)
Depression Characteristics
BDI Total Score, mean (SD)	19.9 (7.2)	18.4 (6.6)
HDRS Total Score, mean (SD)	18.3 (5.5)	18.3 (5.4)
Depression History
Antidepressant Use at Recruitment, No. (%)	19 (8.1)	15 (6.4)
Major depression, No. (%)	39 (16.7)	25 (20.6)
Cardiovascular History
Coronary artery disease, No. (%)	172 (73.5)	159 (67.7)
Myocardial infarction, No. (%)	122 (52.1)	105 (44.7)
Arrhythmia, No. (%)	94 (40.2)	106 (45.1)
Hypertension, No. (%)	212 (90.6)	200 (85.1)
Hyperlipidemia, No. (%)	180 (76.9)	183 (77.9)
Diabetes, No. (%)	126 (53.8)	108 (46)
Renal disease, No. (%)	81 (34.6)	87 (37)
PCI/Stent, No. (%)	83 (35.5)	88 (37.4)
Coronary artery bypass graft surgery, No. (%)	82 (35)	78 (33.2)
Implantable cardioverter defibrillator, No. (%)	45 (19.2)	45 (19.1)
Permanent pacemaker, No. (%)	17 (7.3)	12 (5.1)
Cardiovascular Medications
ACE-inhibitor, No. (%)	165 (71.4)	165 (70.2)
Angiotensin receptor blocker, No. (%)	22 (9.4)	17 (7.2)
Beta blocker, No. (%)	202 (86.3)	194 (82.6)
Loop diuretic, No. (%)	144 (61.5)	147 (62.6)
Digoxin, No. (%)	36 (15.4)	44 (18.7)
Statin, No. (%)	168 (71.8)	158 (67.2)
Aspirin, No. (%)	197 (84.2)	194 (82.6)

^*P=.03